North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 22 of 22
Details
LDL
Link Added : MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation : https://www.gov.uk/drug-safety-update/ipilimumab-yervoy-reports-of-cytomegalovirus-cmv-gastrointestinal-inf
11/07/2023 18:32:07
(dmcdermott )
UPD
NHSE Changed from N
27/07/2022 15:36:52
(DavidS )
UPD
sitematrix Changed from 0 to
27/07/2022 15:36:52
(DavidS )
UPD
BlueTeq Changed from N to Y
27/07/2022 15:36:52
(DavidS )
UPD
isHC Changed from N to Y
27/07/2022 15:36:52
(DavidS )
UPD
isCyto Changed from 0 to 1
27/07/2022 15:36:52
(DavidS )
UPD
Ipilimumab (Yervoy
®
) updated
27/07/2022 15:36:52
(DavidS )
UPD
Published from Draft Mode
27/07/2022 15:04:41
(LoweryM )
UPD
sitematrix Changed from 0 to
27/07/2022 15:03:40
(LoweryM )
UPD
FurtherInformation Changed from
Approved for previously treated advanced melanoma in line with NICE.
Approved for previously untreated advanced melanoma in line with NICE.
Approved in combination with nivolumab for
27/07/2022 15:03:40
(LoweryM )
UPD
Ipilimumab (Yervoy
®
) approved
27/07/2022 15:03:40
(LoweryM )
UPD
sitematrix Changed from 0 to
27/07/2022 14:32:46
(DavidS )
UPD
Ipilimumab (Yervoy
®
) brand name added
27/07/2022 14:32:46
(DavidS )
LDL
Link Added : NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma : https://www.nice.org.uk/guidance/ta780
15/07/2022 09:16:00
(DavidS )
UPD
sitematrix Changed from 0 to
15/07/2022 09:15:34
(DavidS )
UPD
isDraft Changed from N to Y
15/07/2022 09:15:34
(DavidS )
UPD
FurtherInformation Changed from
Approved for previously treated advanced melanoma in line with NICE.
Approved for previously untreated advanced melanoma in line with NICE.
to
Approved for previo
15/07/2022 09:15:34
(DavidS )
UPD
Ipilimumab NICE TA780
15/07/2022 09:15:34
(DavidS )
LDL
Link Added : NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab : https://www.nice.org.uk/guidance/ta357
01/02/2017 15:10:07
(DavidS )
UPD
Ipilimumab b
01/02/2017 15:08:51
(DavidS )
UPD
Ipilimumab b
23/01/2017 11:24:20
(WhitehallJ )
UPD
Ipilimumab (Yervoy
®
) build
28/11/2016 15:44:03
(DavidS )